Table 1 Baseline demographics and characteristics

From: Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial

 

Overall cohorta (HR+ and HR− cohorts)

HR+ cohorta

HR− cohorta

T-DXd

n = 373

TPC

n = 184

T-DXd

n = 331

TPC

n = 163

T-DXd

n = 40

TPC

n = 18

Age, median (range), years

57.5 (31.5–80.2)

55.9 (28.4–80.5)

56.8 (31.5–80.2)

55.7 (28.4–80.0)

58.9 (36.6–78.9)

55.9 (32.6–80.5)

Female, n (%)

371 (99.5)

184 (100)

329 (99.4)

163 (100.0)

40 (100)

18 (100)

Region, n (%)

 Europe or Israel

166 (44.5)

85 (46.2)

149 (45.0)

73 (44.8)

17 (42.5)

10 (55.6)

 Asia

147 (39.4)

66 (35.9)

128 (38.7)

60 (36.8)

19 (47.5)

6 (33.3)

 North America

60 (16.1)

33 (17.9)

54 (16.3)

30 (18.4)

4 (10.0)

2 (11.1)

Race, n (%)

 White

176 (47.2)

91 (49.5)

156 (47.1)

78 (47.9)

19 (47.5)

11 (61.1)

 Asian

151 (40.5)

72 (39.1)

131 (39.6)

66 (40.5)

20 (50.0)

6 (33.3)

 Black

7 (1.9)

3 (1.6)

7 (2.1)

2 (1.2)

0

1 (5.6)

 Native American or native Alaskan

0

0

0

0

0

0

 Native Hawaiian or other Pacific Islander

1 (0.3)

0

0

0

0

0

 Other

38 (10.2)

17 (9.2)

37 (11.2)

16 (9.8)

1 (2.5)

0

 Missing data

0

1 (0.5)

0

1 (0.6)

0

0

Ethnic group, n (%)

 Hispanic or Latino

14 (3.8)

7 (3.8)

14 (4.2)

5 (3.1)

0

1 (5.6)

 Non-Hispanic or non-Latino

308 (82.6)

153 (83.2)

267 (80.7)

137 (84.0)

39 (97.5)

14 (77.8)

 Unknown

9 (2.4)

7 (3.8)

9 (2.7)

4 (2.5)

0

3 (16.7)

 Not applicable

42 (11.3)

17 (9.2)

41 (12.4)

17 (10.4)

1 (2.5)

0

HER2-low status, n (%)

 IHC 1+

214 (57.4)

107 (58.2)

192 (58.0)

96 (58.9)

22 (55.0)

10 (55.6)

 IHC 2+/ISH−

159 (42.6)

77 (41.8)

139 (42.0)

67 (41.1)

18 (45.0)

8 (44.4)

ECOG PS, n (%)

 0

200 (53.6)

105 (57.1)

187 (56.5)

95 (58.3)

14 (35.0)

8 (44.4)

 1

173 (46.4)

79 (42.9)

144 (43.5)

68 (41.7)

26 (65.0)

10 (55.6)

Baseline metastases, n (%)

 CNS

24 (6.4)

8 (4.3)

18 (5.4)

7 (4.3)

5 (12.5)

1 (5.6)

 Liver

266 (71.3)

123 (66.8)

247 (74.6)

116 (71.2)

19 (47.5)

5 (27.8)

 Lung

120 (32.2)

63 (34.2)

98 (29.6)

58 (35.6)

22 (55.0)

5 (27.8)

Prior lines of chemotherapy for metastatic disease

 0–1

222 (59.5)

101 (54.9)

204 (61.6)

94 (57.7)

17 (42.5)

5 (27.8)

 ≥2

151 (40.5)

83 (45.1)

127 (38.4)

69 (42.3)

23 (57.5)

13 (72.2)

  1. Overall and HR+ cohort baseline demographics and characteristics data from ref. 8. Copyright 2025 Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society.
  2. CNS, central nervous system; ECOG PS, Eastern Cooperative Oncology Group performance status.
  3. aOverall cohort includes patients whose HR status was misstratified. For the exploratory analyses of the HR− cohort, HR status is based on data from the electronic data capture that were corrected for misstratification.
Back to article page